These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 29776337

  • 1. Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts.
    Yebyo HG, Aschmann HE, Yu T, Puhan MA.
    BMC Cardiovasc Disord; 2018 May 18; 18(1):97. PubMed ID: 29776337
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study.
    Yebyo HG, Zappacosta S, Aschmann HE, Haile SR, Puhan MA.
    BMC Cardiovasc Disord; 2020 Sep 17; 20(1):418. PubMed ID: 32942999
    [Abstract] [Full Text] [Related]

  • 4. Ethnic differences in guideline-indicated statin initiation for people with type 2 diabetes in UK primary care, 2006-2019: A cohort study.
    Eastwood SV, Mathur R, Sattar N, Smeeth L, Bhaskaran K, Chaturvedi N.
    PLoS Med; 2021 Jun 17; 18(6):e1003672. PubMed ID: 34185782
    [Abstract] [Full Text] [Related]

  • 5. Estimated Cardiovascular Risk and Guideline-Concordant Primary Prevention With Statins: Retrospective Cross-Sectional Analyses of US Ambulatory Visits Using Competing Algorithms.
    Fairman KA, Romanet D, Early NK, Goodlet KJ.
    J Cardiovasc Pharmacol Ther; 2020 Jan 17; 25(1):27-36. PubMed ID: 31353942
    [Abstract] [Full Text] [Related]

  • 6. Time to improve statin prescription guidelines in low-risk patients?
    Balder JW, de Vries JK, Mulder DJ, Kamphuisen PW.
    Eur J Prev Cardiol; 2017 Jul 17; 24(10):1064-1070. PubMed ID: 28429651
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the impact of the recent controversy over statins in France: the EVANS study.
    Saib A, Sabbah L, Perdrix L, Blanchard D, Danchin N, Puymirat E.
    Arch Cardiovasc Dis; 2013 Oct 17; 106(10):511-6. PubMed ID: 24080324
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population-Based Cohort Study.
    Garcia-Gil M, Comas-Cufí M, Blanch J, Martí R, Ponjoan A, Alves-Cabratosa L, Petersen I, Marrugat J, Elosua R, Grau M, Ramos R.
    Clin Pharmacol Ther; 2018 Oct 17; 104(4):719-732. PubMed ID: 29194590
    [Abstract] [Full Text] [Related]

  • 9. Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey.
    Burstein B, Altobelli KK, Williams K, Cannon CP, Pencina MJ, Sniderman AD, Thanassoulis G.
    Circulation; 2017 Nov 07; 136(19):1860-1862. PubMed ID: 29109198
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q, Aertgeerts B, Guyatt G, Bekkering GE, Vandvik PO, Khan SU, Rodondi N, Jackson R, Reny JL, Al Ansary L, Van Driel M, Assendelft WJJ, Agoritsas T, Spencer F, Siemieniuk RAC, Lytvyn L, Heen AF, Zhao Q, Riaz IB, Ramaekers D, Okwen PM, Zhu Y, Dawson A, Ovidiu MC, Vanbrabant W, Li S, Delvaux N.
    BMJ; 2022 May 04; 377():e069066. PubMed ID: 35508320
    [Abstract] [Full Text] [Related]

  • 13. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU, Talluri S, Riaz H, Rahman H, Nasir F, Bin Riaz I, Sattur S, Ahmed H, Kaluski E, Krasuski R.
    Eur J Prev Cardiol; 2018 May 04; 25(8):844-853. PubMed ID: 29569492
    [Abstract] [Full Text] [Related]

  • 14. Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers.
    Akhabue E, Rittner SS, Carroll JE, Crawford PM, Dant L, Laws R, Leo MC, Puro J, Persell SD.
    J Am Heart Assoc; 2017 Jul 03; 6(7):. PubMed ID: 28673901
    [Abstract] [Full Text] [Related]

  • 15. Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry.
    Nanna MG, Navar AM, Wang TY, Mi X, Virani SS, Louie MJ, Lee LV, Goldberg AC, Roger VL, Robinson J, Peterson ED.
    J Am Heart Assoc; 2018 May 08; 7(10):. PubMed ID: 29739801
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Statins in the primary prevention of cardiovascular disease.
    Reiner Ž.
    Nat Rev Cardiol; 2013 Aug 08; 10(8):453-64. PubMed ID: 23736519
    [Abstract] [Full Text] [Related]

  • 18. Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study.
    Yebyo HG, Aschmann HE, Puhan MA.
    Ann Intern Med; 2019 Jan 01; 170(1):1-10. PubMed ID: 30508425
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Statin Discontinuation and Cardiovascular Events Among Older People in Denmark.
    Thompson W, Morin L, Jarbøl DE, Andersen JH, Ernst MT, Nielsen JB, Haastrup P, Schmidt M, Pottegård A.
    JAMA Netw Open; 2021 Dec 01; 4(12):e2136802. PubMed ID: 34854906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.